BACKGROUND: Homozygote carriers of two long (L) alleles of the serotonin transporter (5-HTT) regulatory region displayed in vitro a twofold increase in 5-HTT expression compared with carriers of one or two short (S) alleles. However, in vivo imaging studies yielded contradictory results. Recently, an A > G exchange leading to differential transcriptional activation of 5-HTT mRNA in lymphobalstoid cell lines was discovered in the 5-HTT regulatory region. In vitro and in vivo evidence suggests that [(11)C]DASB, a new 5-HTT ligand offers some advantages over the ligands used in previous studies in measuring 5-HTT density independent of synaptic levels of serotonin. METHOD: We assessed 5-HTT binding potential (BP (2)) in the midbrain of 19 healthy subjects with positron emission tomography and [(11)C]DASB. Accounting for the hypothesized functional similarity of L (G) and S in driving 5-HTT transcription, we assessed whether L (A) L (A) homozygotes display increased midbrain BP (2) compared with carriers of at least one S allele. RESULTS: BP (2) in the midbrain was significantly increased in L (A) L (A) homozygotes compared with carriers of at least one S allele. Interestingly, the genotype effect on the midbrain was significantly different from that on the thalamus and the amygdala where no group differences were detected. CONCLUSIONS: This in vivo study provides further evidence that subjects homozygous for the L (A) allele display increased expression of 5-HTT in the midbrain, the origin of central serotonergic projections.
BACKGROUND: Homozygote carriers of two long (L) alleles of the serotonin transporter (5-HTT) regulatory region displayed in vitro a twofold increase in 5-HTT expression compared with carriers of one or two short (S) alleles. However, in vivo imaging studies yielded contradictory results. Recently, an A > G exchange leading to differential transcriptional activation of 5-HTT mRNA in lymphobalstoid cell lines was discovered in the 5-HTT regulatory region. In vitro and in vivo evidence suggests that [(11)C]DASB, a new 5-HTT ligand offers some advantages over the ligands used in previous studies in measuring 5-HTT density independent of synaptic levels of serotonin. METHOD: We assessed 5-HTT binding potential (BP (2)) in the midbrain of 19 healthy subjects with positron emission tomography and [(11)C]DASB. Accounting for the hypothesized functional similarity of L (G) and S in driving 5-HTT transcription, we assessed whether L (A) L (A) homozygotes display increased midbrain BP (2) compared with carriers of at least one S allele. RESULTS: BP (2) in the midbrain was significantly increased in L (A) L (A) homozygotes compared with carriers of at least one S allele. Interestingly, the genotype effect on the midbrain was significantly different from that on the thalamus and the amygdala where no group differences were detected. CONCLUSIONS: This in vivo study provides further evidence that subjects homozygous for the L (A) allele display increased expression of 5-HTT in the midbrain, the origin of central serotonergic projections.
Authors: René Hummerich; Oliver Schulze; Thomas Rädler; Pal Mikecz; Matthias Reimold; Winfried Brenner; Malte Clausen; Patrick Schloss; Ralph Buchert Journal: Nucl Med Biol Date: 2006-03-09 Impact factor: 2.408
Authors: Xian-Zhang Hu; Robert H Lipsky; Guanshan Zhu; Longina A Akhtar; Julie Taubman; Benjamin D Greenberg; Ke Xu; Paul D Arnold; Margaret A Richter; James L Kennedy; Dennis L Murphy; David Goldman Journal: Am J Hum Genet Date: 2006-03-28 Impact factor: 11.025
Authors: Xianzhang Hu; Gabor Oroszi; Jeffrey Chun; Tom L Smith; David Goldman; Marc A Schuckit Journal: Alcohol Clin Exp Res Date: 2005-01 Impact factor: 3.455
Authors: Peter S Talbot; W Gordon Frankle; Dah-Ren Hwang; Yiyun Huang; Raymond F Suckow; Mark Slifstein; Anissa Abi-Dargham; Marc Laruelle Journal: Synapse Date: 2005-03-01 Impact factor: 2.562
Authors: Carolyn Cidis Meltzer; Julie C Price; Chester A Mathis; Meryl A Butters; Scott K Ziolko; Eydie Moses-Kolko; Sati Mazumdar; Benoit H Mulsant; Patricia R Houck; Brian J Lopresti; Lisa A Weissfeld; Charles F Reynolds Journal: Neuropsychopharmacology Date: 2004-12 Impact factor: 7.853
Authors: M Laruelle; R M Baldwin; R T Malison; Y Zea-Ponce; S S Zoghbi; M S al-Tikriti; E H Sybirska; R C Zimmermann; G Wisniewski; J L Neumeyer Journal: Synapse Date: 1993-04 Impact factor: 2.562
Authors: Ahmad R Hariri; Venkata S Mattay; Alessandro Tessitore; Bhaskar Kolachana; Francesco Fera; David Goldman; Michael F Egan; Daniel R Weinberger Journal: Science Date: 2002-07-19 Impact factor: 47.728
Authors: Patrick M Fisher; Cheryl L Grady; Martin K Madsen; Stephen C Strother; Gitte M Knudsen Journal: Hum Brain Mapp Date: 2015-04-30 Impact factor: 5.038
Authors: Karine Madsen; David Erritzoe; Erik Lykke Mortensen; Anders Gade; Jacob Madsen; William Baaré; Gitte M Knudsen; Steen G Hasselbalch Journal: Psychopharmacology (Berl) Date: 2010-07-10 Impact factor: 4.530
Authors: M Reimold; M N Smolka; A Zimmer; A Batra; A Knobel; C Solbach; A Mundt; H U Smoltczyk; D Goldman; K Mann; G Reischl; H-J Machulla; R Bares; A Heinz Journal: J Neural Transm (Vienna) Date: 2007-08-22 Impact factor: 3.575
Authors: Dennis L Murphy; Meredith A Fox; Kiara R Timpano; Pablo R Moya; Renee Ren-Patterson; Anne M Andrews; Andrew Holmes; Klaus-Peter Lesch; Jens R Wendland Journal: Neuropharmacology Date: 2008-09-11 Impact factor: 5.250
Authors: Jeffrey M Miller; Erin L Kinnally; R Todd Ogden; Maria A Oquendo; J John Mann; Ramin V Parsey Journal: Synapse Date: 2009-07 Impact factor: 2.562